Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL3261023 | 1.00 | ALDH1A1 (0.58) | ALDH1A1LMNASMN1; SMN2MAPTKDM4E | |
| Pyridine SCHEMBL31483849 | 1.00 | ALDH1A1 (0.58) | ALDH1A1LMNASMN1; SMN2MAPTKDM4E | |
| Pyridine SCHEMBL6427981 | 1.00 | ALDH1A1 (0.58) | ALDH1A1LMNASMN1; SMN2MAPTKDM4E | |
| Pyridine SCHEMBL7656088 | 1.00 | ALDH1A1 (0.58) | ALDH1A1LMNASMN1; SMN2MAPTKDM4E | |
| Pyridine SCHEMBL20958 | 1.00 | ALDH1A1 (0.58) | ALDH1A1LMNASMN1; SMN2MAPTKDM4E | |
| Pyridine SCHEMBL28227884 | 0.98 | ALDH1A1 (0.57) | ALDH1A1LMNASMN1; SMN2MAPTKDM4E | |
| Pyridine SCHEMBL28166378 | 0.98 | ALDH1A1 (0.57) | ALDH1A1LMNASMN1; SMN2MAPTKDM4E | |
| Pyridine SCHEMBL28538739 | 0.98 | ALDH1A1 (0.57) | ALDH1A1LMNASMN1; SMN2MAPTKDM4E | |
| Pyridine SCHEMBL28981792 | 0.98 | ALDH1A1 (0.57) | ALDH1A1LMNASMN1; SMN2MAPTKDM4E | |
| Pyridine SCHEMBL5968326 | 0.98 | ALDH1A1 (0.57) | ALDH1A1LMNASMN1; SMN2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844376-B2 | Structurally-enhanced miRNA inhibitor S-TuD | UNIVERSITY OF TOKYO (JP) | 2020-11-24 | — | — | US | disclosed |
| US-20200032262-A1 | NOVEL TECHNIQUE FOR TREATING CANCER USING STRUCTURALLY-REINFORCED S-TUD | GENEDESIGN, INC. (JP) | 2020-01-30 | — | — | US | disclosed |
| US-20180223281-A1 | STRUCTURALLY-ENHANCED miRNA INHIBITOR S-TuD | THE UNIVERSITY OF TOKYO (JP) | 2018-08-09 | — | — | US | disclosed |
| EP-3351632-A1 | STRUCTURALLY-ENHANCED miRNA INHIBITOR S-TUD | The University Of Tokyo (JP) | 2018-07-25 | — | — | EP | disclosed |
| EP-1661905-B9 | NOVEL ARTIFICIAL NUCLEIC ACIDS OF N-O BOND CROSSLINKAGE TYPE | IMANISHI TAKESHI (JP) | 2012-12-19 | — | — | EP | disclosed |
| EP-1661905-B1 | NOVEL ARTIFICIAL NUCLEIC ACIDS OF N-O BOND CROSSLINKAGE TYPE | IMANISHI TAKESHI (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-7427672-B2 | Artificial nucleic acids of n-o bond crosslinkage type | Imanishi, Takeshi (JP) | 2008-09-23 | — | — | US | disclosed |
| US-20070167387-A1 | Novel artificial nucleic acids of n-o bond crosslinkage type | TAKESHI IMANISHI (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1661905-A1 | NOVEL ARTIFICIAL NUCLEIC ACIDS OF N-O BOND CROSSLINKAGE TYPE | Gene Design, Inc. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200032262-A1 | NOVEL TECHNIQUE FOR TREATING CANCER USING STRUCTURALLY-REINFORCED S-TUD | SLIRP, HNRNPDL, KHDRBS1 | EGFR 3289/4885ALDH1A1 4027/4885LMNA 2108/4885 |
| US-10844376-B2 | Structurally-enhanced miRNA inhibitor S-TuD | SLIRP, AGO2, KHDRBS1 | EGFR 4473/4885ALDH1A1 3417/4885LMNA 2667/4885 |
| US-20070167387-A1 | Novel artificial nucleic acids of n-o bond crosslinkage type | RNGTT, NSUN2, POLR2H | EGFR 4692/4885ALDH1A1 1271/4885LMNA 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.